Clinical study of aspirin combined with simvastatin in the prevention and treatment of ischemic cerebrovascular disease
阿司匹林联合辛伐他汀防治缺血性脑血管病临床研究

摘要

目的 探讨在缺血性脑血管病防治中采用阿司匹林联合辛伐他汀的临床效果。方法 以我院收治的冠心病心力衰竭患者作为本研究的主要分析对象，研究开展时间为2020年6月，结束时间为2021年6月，在此期间选取缺血性脑血管疾病患者80例并设立参照组和研究组两个小组，将患者依据计算机随机分组的方法，以每组40例均为至两组，同时为了凸显出本研究中防治方法的效果，对不同分组的患者应用不同的治疗方式，以此完成对照研究，其中前者的治疗方法是阿司匹林，后者的治疗方法为联合治疗即阿司匹林+辛伐他汀。上述治疗方法实施后，需要详细地记录相关数据，尤其是患者接受治疗后的临床效果和1年后的随访结果，更应详细统计，并对比两组的实际情况。结果 对两组患者治疗后的结果进行统计发现，｛参照组67.5%（28/40）比研究组85.0%（34/40）}，以上数据后者有显著优势（P＜0.05），差异和统计学意义明显。患者接受治疗后进行为期1年的随访，研究组中心肌梗死、短暂性脑缺血、脑梗死和死亡的患者分别有2例、2例、1例、1例，参照组分别有4例、5例、3例、2例，数据记录后比较，后者例数较高，差异有统计学意义（P＜0.05）。结论 使用阿司匹林联合辛伐他汀进行缺血性脑血管病的治疗，不仅能够提高患者的临床效果，还能够促进安全性的提高，在今后治疗后可拓宽推广和应用价值。

Abstract

Objective: To investigate the clinical effect of aspirin combined with simvastatin in the prevention and treatment of ischemic cerebrovascular disease.
Methods: The patients with coronary heart disease and heart failure admitted to our hospital were the main analysis objects of this study. The study was carried out in June 2020 and ended in June 2021. During this period, 80 patients with ischemic cerebrovascular disease were selected. And set up two groups, the reference group and the study group, and randomly group the patients according to the method of computer. The 40 cases in each group are divided into two groups. At the same time, in order to highlight the effect of the prevention and treatment methods in this study, different applications are applied to patients in different groups. In order to complete the controlled study, the treatment method of the former is aspirin, and the treatment method of the latter is the combination therapy, namely aspirin + simvastatin. After the above treatment methods are implemented, relevant data needs to be recorded in detail, especially the clinical effects of patients after treatment and the follow-up results after 1 year. Detailed statistics should be made and the actual situation of the two groups should be compared.
Results: The statistical results of the two groups of patients after treatment showed that {reference group 67.5% (28/40) compared to the study group 85.0% (34/40)}, the latter has a significant advantage (P<0.05), the difference is And statistically significant. The patients were followed up for 1 year after treatment. In the study group, there were 2 cases, 2 cases, 1 case, and 1 case of myocardial infarction, transient cerebral ischemia, cerebral infarction, and death, respectively, and the reference group had 4 cases, respectively. In 5 cases, 3 cases, and 2 cases, after data recording, the latter had a higher number of cases, and the difference was statistically significant (P<0.05).
Conclusion  : The use of aspirin combined with simvastatin for the treatment of ischemic cerebrovascular disease can not only improve the clinical effect of patients, but also promote the improvement of safety, which can broaden the promotion and application value after treatment in the future.